MedTrace Logo

Evaluation of NT-proBNP in Chronic Inflammatory Bowel Disease

NCT03107390 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2020-07-15

No results posted yet for this study

Summary

NT-proBNP is a major diagnostic and prognostic marker in cardiology, but it is also a new marker for biological inflammation, especially in rheumatology.

Its evaluation in chronic inflammatory bowel disease was carried out in a preliminary study, the OPERA study where in a population of 12 patients showed an increase in NT-proBNP correlated with the biological and endoscopic activity of the disease. This larger study is therefore a pilot study that could see NTproBNP as a new biomarker of inflammation in MICI.

Conditions

  • Inflammatory Bowel Diseases
  • NT-pro-BNP

Interventions

OTHER

Evaluate the blood level of NTproBNP

Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.

Sponsors & Collaborators

  • Centre Hospitalier Universitaire, Amiens

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-28
Primary Completion
2017-08-07
Completion
2017-08-07

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03107390 on ClinicalTrials.gov